Blogs Understanding the CHRM1 Receptor: Biology, Function, and Emerging Tools for Drug Discovery

Understanding the CHRM1 Receptor: Biology, Function, and Emerging Tools for Drug Discovery

What Is CHRM1?

CHRM1 encodes the M1 muscarinic acetylcholine receptor, a Class A G protein–coupled receptor (GPCR) that mediates many of the central nervous system (CNS) effects of acetylcholine (ACh). Among the five muscarinic receptor subtypes (M1-M5), CHRM1 is the most abundant in the cortex and hippocampus; regions critical for learning, memory, and executive function.

Main SRCL Header

Unlike the inhibitory M2 and M4 receptors, CHRM1 primarily couples to Gαq/11 proteins. Upon activation, it stimulates phospholipase C (PLC), triggering IP₃ and DAG production, intracellular calcium release, and downstream protein kinase C (PKC) activation. This calcium-dependent signaling cascade enhances neuronal excitability and synaptic plasticity, positioning CHRM1 as a regulator of higher-order cognitive processes.

CHRM1 Within the Muscarinic Receptor Family

Muscarinic acetylcholine receptors comprise five GPCR subtypes with distinct signaling profiles and tissue distributions. While all respond to acetylcholine, they diverge functionally:

  • M1, M3, and M5 are primarily Gαq-coupled and promote excitatory signaling through calcium mobilization.
  • M2 and M4 are primarily Gαi/o-coupled and reduce cAMP levels, exerting inhibitory effects.

CHRM1 stands out for its role in CNS cognition. Because muscarinic receptors share a conserved binding site, achieving subtype selectivity has historically been challenging, making CHRM1 both scientifically intriguing and pharmacologically complex.

Therapeutic Relevance of CHRM1

Cognitive Function and Alzheimer’s Disease

Schizophrenia involves cognitive deficits and negative symptoms that are often insufficiently addressed by dopamine-targeted therapies. Emerging data indicate that reduced CHRM1 expression or function may contribute to these impairments.

Selective M1-preferring agonists and M1/M4 modulators have shown promise in clinical research, offering a non-dopaminergic mechanism for cognitive enhancement and symptom management. Because CHRM1 enhances cortical signaling and information processing, it remains a compelling target for next-generation neuropsychiatric therapeutics.

While CHRM1 activation enhances cognition, excessive or non-selective cholinergic stimulation can lead to peripheral side effects such as gastrointestinal distress, salivation, and cardiovascular changes. These effects are often mediated by M2 and M3 receptors outside the CNS.

To address this, modern drug discovery efforts increasingly focus on allosteric modulation. Positive allosteric modulators (PAMs) bind to sites distinct from the acetylcholine-binding pocket, improving subtype selectivity and enabling activity-dependent amplification of endogenous signaling. This approach allows researchers to fine-tune CHRM1 activation while minimizing systemic cholinergic burden.

Schizophrenia and Neuropsychiatric Disorders

Balancing Excitability and Safety

Alzheimer's disease is characterized by progressive cholinergic neuron loss, particularly in cortical and hippocampal pathways. Current acetylcholinesterase inhibitors raise synaptic acetylcholine globally, but they do not selectively enhance CHRM1 signaling.

Targeted CHRM1 activation represents a more refined strategy. Preclinical research suggests that M1 stimulation can enhance long-term potentiation (LTP), improve working memory, and shift amyloid precursor protein (APP) processing toward non-amyloidogenic pathways. Additionally, CHRM1 signaling has been associated with reduced tau phosphorylation, making it relevant not only for symptomatic treatment but potentially for disease modification.

INDIGO’s CHRM1 Reporter Assay Platform

INDIGO Biosciences supports CNS drug discovery with ready-to-use CHRM1 reporter assays, offered in an activation or inhibition format, that are designed for streamlined, high-sensitivity evaluation of receptor pharmacology.

The assays utilize transiently transfected CHRM1 reporter cells coupled to a pathway-responsive luciferase readout, enabling detection of receptor activation through Gαq-mediated signaling. Provided in a convenient, ready-to-use plate format with a reference agonist or antagonist included, the system supports agonist, antagonist, and allosteric modulator testing in 96-well and 3×32-well configurations.

Powered by INDIGO’s proprietary CryoMite™ cryopreservation technology, researchers can bypass continuous cell culture maintenance and generate reproducible data in as little as 24 hours. This platform enables efficient screening, lead optimization, and subtype selectivity profiling—critical steps in advancing CNS-targeted therapeutics.

The CHRM1 receptor occupies a central position in cholinergic regulation of cognition, synaptic plasticity, and cortical signaling. Its involvement in Alzheimer’s disease, schizophrenia, and broader neuropsychiatric disorders underscores its therapeutic significance.

As drug discovery strategies evolve toward subtype-selective and allosteric modulation, CHRM1 continues to emerge as a high-value GPCR target. With advanced reporter assay tools, researchers can more precisely interrogate M1 pharmacology and accelerate the development of next-generation cognitive therapeutics.

References

Fisher, A., Michaelson, D. M., Brandeis, R., Haring, R., Chapman, S., & Pittel, Z. (2000). M1 muscarinic agonists as potential disease-modifying agents in Alzheimer's disease. Rationale and perspectives. Annals of the New York Academy of Sciences, 920, 315–320. https://doi.org/10.1111/j.1749-6632.2000.tb06941.x

Patel, N. M., & Dewaswala, N. (2023, April 26). Parasympathomimetic medications. StatPearls [Internet]. https://www.ncbi.nlm.nih.gov/books/NBK554534/

Scarr, E., Craig, J. M., Cairns, M. J., Seo, M. S., Galati, J. C., Beveridge, N. J., Gibbons, A., Juzva, S., Weinrich, B., Parkinson-Bates, M., Carroll, A. P., Saffery, R., & Dean, B. (2013). Decreased cortical muscarinic M1 receptors in schizophrenia are associated with changes in gene promoter methylation, mRNA and gene targeting microRNA. Translational psychiatry, 3(2), e230. https://doi.org/10.1038/tp.2013.3